5th Annual Induced Proximity-Based Drug Discovery Summit
Aiming to push the frontier of induced proximity drugs and expand the therapeutic capacity of novel MoA’s, the 5th Annual Induced Proximity-Based Drug Discovery Summit returns with 2 days of exclusive insights to overcome key bottlenecks and address burning questions including:
How to refine target identification for improved selectivity, functional relevance, and clinical translatability?
How to reproduce academic literature in an industrial setting to stay competitive in a rapidly expanding landscape of viable MoA’s?
How can AI & ML enhance ternary complex formation prediction to accelerate drug design and reduce medicinal chemistry burdens?
How can next-gen screening and assay development tools streamline hit-to-lead workflows and rapidly validate induced proximity mechanisms?
How to navigate novel MoA’s to avoid pitfalls, leverage best practices and accelerate success in degrader and non-degrader drug discovery?
How can biotech, pharma, and academia position their assets to attract investment and secure critical funding for pipeline acceleration?
Attending Companies Include:
What's New?
Next-Gen MoAs & Expanded Therapeutic Scope – Cutting-edge insights into RIPTACs, DUBTACs, RIBOTACs, tPRIMEs, Non-degrading Molecular Glues, and novel protein stabilizers, with a focus on improving selectivity, safety, and clinical viability.
Exclusive AI & Machine Learning Insights – Deep-dive sessions from Genentech, Arrakis, Novo Nordisk & Vicinitas showcasing how AI-driven modeling, active learning, and bioinformatics are optimizing target discovery, validation, and ternary complex optimization.
New Speaker Lineup & Industry Leaders – Fresh insights from Halda, Photys, Stablix, Novartis, Harvard, A-Alpha, Plexium and more, to enable you to walk away with the tools to accelerate your induced proximity candidates to the clinic.
Deep-Dive into Investment Strategies – Dedicated Investment Roundtable with Astellas Ventures to explore how biotech, academia, and pharma can position their induced proximity assets to secure funding and de-risk clinical translation.